| Literature DB >> 32053684 |
Juliana Ayres Hutter1, Réjean Dion2,3, Alejandra Irace-Cima1, Marc Fiset4, Rebecca Guy5, Brent Dixon6, Jeannie Lisette Aguilar2, Julien Trépanier2, Karine Thivierge2,7.
Abstract
The aim of this study was to describe the epidemiology of human cryptosporidiosis in Québec from 2016 to 2017 and to identify possible exposures associated with the disease, and the dominant Cryptosporidium species in circulation. A descriptive analysis was performed on data collected from the provincial notifiable infectious diseases registry and the epidemiological investigation. Fecal sample were sent to the Laboratoire de santé publique du Québec for molecular characterization. In Québec, from January 1, 2016 to December 31, 2017, a total of 201 confirmed cases of cryptosporidiosis were notified. A peak in the number of reported cases was observed at the end of the summer. The regional public health department with the highest adjusted incidence rate for sex and age group for both years was that of Nunavik, in the north of Québec. A higher average annual incidence rate was observed for females between the ages of 20 to 34 years compared to males. Overall, for both males and females the distribution appeared to be bimodal with a first peak in children younger than five years old and a second peak in adults from 20 to 30 years of age. Molecular characterization showed that 23% (11/47) of cases were infected with C. hominis while 74% (35/47) were infected with C. parvum. Meanwhile, subtyping results identified by gp60 sequencing, show that all C. parvum subtypes belonged to the IIa family, whereas the subtypes for C. hominis belonged to the Ia, Ib, and Id families. Finally, the epidemiological investigation showed that diarrhea was the most common reported symptom with 99% (72/73) of investigated cases having experienced it. This first brief epidemiological portrait of cryptosporidiosis in Québec has allowed for the description, both at the provincial and regional level, of the populations that could be particularly vulnerable to the disease.Entities:
Year: 2020 PMID: 32053684 PMCID: PMC7018055 DOI: 10.1371/journal.pone.0228986
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Number and crude incidence rate of reported cases by month of notification, 2016–2017.
Crude incidence rate per 100,000 population.
Number, percentage and sex and age-adjusted incidence rate of confirmed reported cases by health region of residence (HRR) in Québec, Canada, 2016–2017.
| HRR | 2016 | 2017 | ||
|---|---|---|---|---|
| Incidence rate | Incidence rate | |||
| Bas-Saint-Laurent | - | - | 2 (2.2) | 1.17 |
| Capitale-Nationale | 4 (3.6) | 0.53 | 1 (1.1) | 0.12 |
| Estrie | 13 (11.6) | 2.85 | 4 (4.5) | 0.90 |
| Montréal | 13 (11.6) | 0.58 | 16 (18.0) | 0.70 |
| Outaouais | 4 (3.6) | 0.73 | 4 (4.5) | 0.98 |
| Abitibi-Témiscamingue | 3 (2.7) | 2.00 | 4 (4.5) | 2.69 |
| Chaudière-Appalaches | 38 (33.9) | 9.43 | 28 (31.5) | 6.96 |
| Laval | 2 (1.8) | 0.41 | 1 (1.1) | 0.22 |
| Lanaudière | 7 (6.3) | 1.34 | 4 (4.5) | 0.78 |
| Laurentides | 21 (18.8) | 3.73 | 17 (19.1) | 2.93 |
| Montérégie | 6 (5.4) | 0.35 | 7 (7.9) | 0.49 |
| Nunavik | 1 (0.9) | 15.05 | 1 (1.1) | 7.78 |
Age and sex-adjusted incidence rate for 100,000 population
Fig 2Number and average annual crude incidence rate of cases by age group and sex, 2016–2017.
Average annual crude incidence rate for 100,000 population.
Number and percentage of confirmed reported cases by Cryptosporidium species in Québec, Canada, 2016–2017.
| Variable | ||||
|---|---|---|---|---|
| 2016 | 2017 | 2016 | 2017 | |
| Male | 16 (73) | 7 (54) | - | 2 (33) |
| Female | 6 (27) | 6 (46) | 4 (100) | 4 (67) |
| <15 | 9 (41) | 2 (15) | 2 (50) | 3 (50) |
| 15–29 | 7 (32) | 5 (38) | - | 2 (33) |
| 30–44 | 5 (23) | 4 (31) | 1 (25) | 1 (17) |
| 45–59 | - | 1 (8) | 1 (25) | - |
| 60–74 | - | - | - | - |
| 75–84 | - | - | - | - |
| ≥85 | 1 (5) | - | - | - |
| Missing | - | 1 (8) | - | - |
| Capitale-Nationale | 1 (5) | - | - | - |
| Mauricie et Centre-du-Québec | - | 1 (8) | - | - |
| Estrie | 1 (5) | - | - | - |
| Nord-du-Québec | - | 1 (8) | - | - |
| Chaudière-Appalaches | 17 (77) | 9 (69) | 1 (25) | 4 (67) |
| Laurentides | 1 (5) | - | - | - |
| Montérégie | 1 (5) | 1 (8) | 3 (75) | 2 (33) |
| Missing | 1 (5) | 1 (8) | - | - |
| Total | 22 (100) | 13 (100) | 4 (100) | 6 (100) |
Number and percentage of confirmed reported cases by Cryptosporidium subtype in Québec, Canada, 2016–2017.
| Subtype | |
|---|---|
| 1 (3) | |
| 1 (3) | |
| 6 (17) | |
| 2 (6) | |
| 1 (3) | |
| 13 (37) | |
| 4 (11) | |
| 3 (9) | |
| 2 (6) | |
| 2 (6) | |
| Total | 35 (100) |
Number and percentage of investigated cases by health region of residence (HRR) in Québec, Canada, 2016–2017.
| HRR | |
|---|---|
| Capitale-Nationale | 4 (5) |
| Estrie | 6 (8) |
| Abitibi-Témiscamingue | 7 (10) |
| Chaudière-Appalaches | 12 (16) |
| Laval | 2 (3) |
| Lanaudière | 9 (12) |
| Laurentides | 30 (41) |
| Montérégie | 3 (4) |
| Total | 73 (100) |
Number and percentage of investigated cases by reported symptoms in Québec, Canada, 2016–2017.
| Symptoms | |
|---|---|
| Diarrhea | 72 (99) |
| Nausea | 25 (34) |
| Vomiting | 27 (37) |
| Abdominal cramps | 54 (74) |
| Fatigue | 36 (49) |
| Appetite loss | 42 (58) |
| Dehydration | 17 (23) |
| Fever | 27 (37) |
| Weight loss | 25 (34) |
| Other clinical manifestations | 11 (15) |
| Total | 73 (100) |